Press Releases

Press Releases

View all news
Voronoi's HER2-Positive Solid Tumor Therapy Selected for Korea Drug Development Fund Project
2023.07.04
⚫ 'Excellent' efficacy, safety, and brain penetrance... Combination effect with antibody-based therapies expected

Voronoi (CEOs Daekwon Kim and Hyuntae Kim), a global drug design company, announced on the 4th that 'VRN10,' which it is developing as a targeted therapy for HER2-positive solid tumors, has been selected as a non-clinical project of the Korea Drug Development Fund (KDDF, Director Hyunsang Mook).

With this selection for the Korea Drug Development Fund project, Voronoi will receive two years of R&D funding for non-clinical research on VRN10.

VRN10 is a targeted therapy that binds specifically to the HER2-positive protein, the cause of breast cancer and various other solid tumors, and strongly inhibits downstream signaling; its high efficacy and safety have been confirmed in experiments. In particular, with higher brain penetrance than competing drugs, it has shown the potential to be developed as a therapy that meets the 'unmet need' for a drug that can penetrate the brain from the early stages of brain metastasis. It is expected to be applicable in combination regimens with the antibody-drug conjugate (ADC) therapies currently used for breast cancer and other indications.

CEO Daekwon Kim of Voronoi said, "The selection for the Korea Drug Development Fund project allows us to accelerate R&D on VRN10. We plan to enter a Phase 1 clinical trial next year."
Based on its unrivaled drug design technology, Voronoi has developed numerous compounds with exceptionally high selectivity and blood-brain-barrier penetration, completing a total of five license-out deals since 2020, including four license-out deals to the U.S. Its cumulative license-out track record amounts to approximately KRW 3 trillion (USD 2,272.7 million).